US$ 29.69
bpc 157 parkinsons and parkinson's Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome What is BPC-157? | Everything
Description
Maximum: Up to ~750 mcg per injection, multiple times daily, per advanced reference protocols

intracellular half-life is prolonged because of lysosomal release and cytosolic resequestration, creating a depot effect that supports monthly maintenance dosing for chronic deficiencies

Direct contact between the peptide and esophageal tissue during swallowing provides local exposure in addition to systemic effects achieved after absorption

60 Suppl 7 (7), 107114
